Celltrion is a major South Korean biopharmaceutical company offering CDMO services for biologics, biosimilars, and small molecules. The company operates production capacities from 1,000L to 15,000L with a 98.5% batch success rate across 2,100+ cGMP drug substance batches, holding 400+ regulatory approvals in 90+ countries. Celltrion recently acquired Eli Lilly's Branchburg, New Jersey facility and launched Celltrion BioSolutions as a dedicated CDMO subsidiary, with plans to expand DS capacity to 132,000L by 2030.
Biosimilar manufacturing, biologics CDMO, ADC development, PFS/auto-injector CMO, monoclonal antibodies, bispecific antibodies
1 site worldwide
Involvement in 10 clinical trials
No reviews available yet.
No documents available.